Lantern Pharma

LP-184, a next-gen alkylating agent, received 3 rare pediatric disease designations from the FDA for treating malignant rhabdoid tumors, rhabdomyosarcoma, and hepatoblastoma. The agent leverages synthetic lethality to target tumor cells and is currently in a phase 1 trial for advanced solid tumors.

Lantern Pharma received FDA's rare pediatric disease designation for LP-184 in Malignant Rhabdoid Tumors, Rhabdomyosarcoma, and Hepatoblastoma, bringing the total to 4. LP-184 showed tumor regression and extended event-free survival in pediatric preclinical models, with potential for a Priority Review Voucher upon FDA approval.

Mantle cell lymphoma (MCL) treatment outcomes improve with novel targeted therapies like BTK inhibitors. DelveInsight's 'Mantle Cell Lymphoma Pipeline Insight 2024' covers 20+ companies developing 22+ therapies, including Venetoclax and ADI-001. Key events include AstraZeneca's Phase III ECHO trial and BeiGene's AACR presentation.

The global cancer biomarkers market size was USD 31.90 billion in 2023 and is projected to reach USD 107.33 billion by 2033, growing at a CAGR of 12.9%. Key drivers include rising technical developments, individualized treatment approaches, and increasing prevalence of cancer globally. The breast cancer segment led the market in 2023, while the genetic biomarkers segment dominated in terms of revenue. North America held the largest market share in 2023, with the U.S. leading due to high prevalence of renal cancer and strong pipeline. Technological innovations and advancements in personalized medicine are expected to further fuel market growth.